|
US6482404B1
(en)
|
1989-10-12 |
2002-11-19 |
David James White |
Transplantation of tissue comprising a DNA sequence encoding a homologous complement restriction factor
|
|
US5866402A
(en)
*
|
1995-05-05 |
1999-02-02 |
Chiron Corporation |
Chimeric MCP and DAF proteins with cell surface localizing domain
|
|
FR2736916B1
(fr)
*
|
1995-07-21 |
1997-09-19 |
Univ Paris Curie |
Proteines hetero-multimeriques recombinantes du type alpha-beta c4bp
|
|
CA2298475A1
(en)
*
|
1997-10-31 |
1999-05-14 |
Walter Reed Army Institute Of Research |
Method of inhibiting side effects of pharmaceutical compositions containing amphiphilic vehicles or drug carrier molecules
|
|
US6956107B2
(en)
*
|
1998-02-20 |
2005-10-18 |
Tanox, Inc. |
Inhibitors of complement activation
|
|
US7112327B2
(en)
*
|
1998-02-20 |
2006-09-26 |
Tanox, Inc. |
Inhibition of complement activation
|
|
JP4437192B2
(ja)
*
|
1998-02-20 |
2010-03-24 |
タノックス インコーポレイテッド |
補体活性化阻害剤
|
|
US6297024B1
(en)
|
1998-10-15 |
2001-10-02 |
Cell Activation, Inc. |
Methods for assessing complement activation
|
|
US6235494B1
(en)
|
1999-02-08 |
2001-05-22 |
The Scripps Research Institute |
Substrates for assessing mannan-binding protein-associated serine protease activity and methods using the substrates
|
|
US6316253B1
(en)
|
1999-11-01 |
2001-11-13 |
Chiron Corporation |
Expression vectors, transfection systems, and method of use thereof
|
|
EP2896631A1
(en)
|
2000-10-10 |
2015-07-22 |
Genentech, Inc. |
Inhibition of complement C5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
|
|
US6820011B2
(en)
*
|
2001-04-11 |
2004-11-16 |
The Regents Of The University Of Colorado |
Three-dimensional structure of complement receptor type 2 and uses thereof
|
|
BR0209319A
(pt)
*
|
2001-06-08 |
2004-07-20 |
Novartis Ag |
Tratamento ou profilaxia de rejeição de enxerto de célula produtora de insulina
|
|
EP1539811A4
(en)
*
|
2002-09-16 |
2006-05-24 |
Elusys Therapeutics Inc |
PREPARATION OF BISPEQIFIC MOLECULES WITH POLYETHYLENE GLYCOL LINKER
|
|
AU2003298650B2
(en)
*
|
2002-11-15 |
2010-03-11 |
Musc Foundation For Research Development |
Complement receptor 2 targeted complement modulators
|
|
WO2005069726A2
(en)
|
2004-01-21 |
2005-08-04 |
Case Western Reserve University |
Hybrid and chimeric polypeptides that regulate activation of complement
|
|
BRPI0506629A
(pt)
*
|
2004-02-10 |
2007-05-02 |
Univ Colorado |
inibição do fator b, a via alternativa do sistema complemento e métodos relacionados
|
|
JP4914344B2
(ja)
*
|
2004-03-31 |
2012-04-11 |
ザ・フェインスタイン・インスティチュート・フォー・メディカル・リサーチ |
虚血／再灌流障害治療用のアドレノメデュリン及びアドレノメデュリン結合タンパク質
|
|
US8703693B2
(en)
*
|
2004-03-31 |
2014-04-22 |
The Feinstein Institute For Medical Research |
Adrenomedullin and adrenomedullin binding protein for ischemia/reperfusion treatment
|
|
WO2006128006A1
(en)
*
|
2005-05-26 |
2006-11-30 |
The Regents Of The University Of Colorado |
Inhibition of the alternative complement pathway for treatment of traumatic brain injury, spinal cord injury and related conditions
|
|
SG10201804008UA
(en)
*
|
2005-11-04 |
2018-06-28 |
Genentech Inc |
Use of complement pathway inhibitors to treat ocular diseases
|
|
US7759304B2
(en)
*
|
2006-06-21 |
2010-07-20 |
Regents Of The University Of Colorado |
Targeting complement factor H for treatment of diseases
|
|
TW201716437A
(zh)
*
|
2006-11-02 |
2017-05-16 |
建南德克公司 |
人類化之抗-因子ｄ抗體及其用途
|
|
JP5332064B2
(ja)
*
|
2007-03-01 |
2013-11-06 |
ウェルスタット イムノセラピューティクス， エルエルシー |
炎症により特徴付けられる疾患の治療
|
|
CN101668773B
(zh)
|
2007-03-14 |
2016-08-31 |
亚力史制药公司 |
人工程化抗b因子抗体
|
|
CR20170001A
(es)
|
2008-04-28 |
2017-08-10 |
Genentech Inc |
Anticuerpos anti factor d humanizados
|
|
WO2009151634A1
(en)
*
|
2008-06-12 |
2009-12-17 |
The Board Of Trustees Of The Leland Stanford Junior University |
Complement inhibitory agents as therapeutics in posttraumatic and degenerative arthritis
|
|
WO2011003098A1
(en)
|
2009-07-02 |
2011-01-06 |
Musc Foundation For Research Development |
Methods of stimulating liver regeneration
|
|
CA2795311A1
(en)
|
2009-11-05 |
2011-05-12 |
Taligen Therapeutics, Inc. |
Treatment of paroxysmal nocturnal hemoglobinuria, hemolytic anemias and disease states involving intravascular and extravascular hemolysis
|
|
CN102234332B
(zh)
*
|
2010-04-26 |
2014-12-17 |
浙江海正药业股份有限公司 |
一种重组人血白蛋白及其融合蛋白的分离纯化工艺
|
|
BR112012029067A2
(pt)
|
2010-05-14 |
2019-09-24 |
Univ Colorado Regents |
grupos-alvo de receptor do complemento 2 (cr2) melhorados.
|
|
SG186397A1
(en)
|
2010-06-22 |
2013-01-30 |
Univ Colorado Regents |
Antibodies to the c3d fragment of complement component 3
|
|
AU2011295715B9
(en)
|
2010-09-03 |
2017-02-23 |
Abbvie Stemcentrx Llc |
Novel modulators and methods of use
|
|
EP3524258B1
(en)
|
2011-06-22 |
2025-10-01 |
Apellis Pharmaceuticals, Inc. |
Methods of treating chronic disorders with complement inhibitors
|
|
US9243070B2
(en)
|
2012-04-03 |
2016-01-26 |
Novelmed Therapeutics, Inc. |
Humanized and chimeric anti-factor Bb antibodies and uses thereof
|
|
US9803005B2
(en)
|
2012-05-24 |
2017-10-31 |
Alexion Pharmaceuticals, Inc. |
Humaneered anti-factor B antibody
|
|
US10413620B2
(en)
|
2012-08-17 |
2019-09-17 |
The Regents Of The University Of Colorado, A Body Corporate |
Light-emitting versions of the monoclonal antibody to C3D (MAB 3D29) for imaging
|
|
JP2015535212A
(ja)
|
2012-08-17 |
2015-12-10 |
ザ・リージエンツ・オブ・ザ・ユニバーシテイ・オブ・コロラド、ア・ボデイー・コーポレイト |
補体活性化を検出するための組成物および方法
|
|
SG11201601044XA
(en)
|
2013-08-12 |
2016-03-30 |
Genentech Inc |
Compositions and method for treating complement-associated conditions
|
|
CN110724691A
(zh)
|
2014-02-27 |
2020-01-24 |
阿勒根公司 |
补体因子Bb抗体
|
|
AU2015253042A1
(en)
|
2014-05-01 |
2016-10-20 |
Genentech, Inc. |
Anti-factor D antibody variants and uses thereof
|
|
EP3633371A1
(en)
|
2014-12-18 |
2020-04-08 |
F. Hoffmann-La Roche AG |
Assay and method for determining cdc eliciting antibodies
|
|
CN108291216B
(zh)
|
2015-09-24 |
2022-09-16 |
宾夕法尼亚州大学信托人 |
用于治疗补体介导的疾病的组合物和方法
|
|
US10407510B2
(en)
|
2015-10-30 |
2019-09-10 |
Genentech, Inc. |
Anti-factor D antibodies and conjugates
|
|
EP3368090A1
(en)
|
2015-10-30 |
2018-09-05 |
H. Hoffnabb-La Roche Ag |
Anti-factor d antibody variant conjugates and uses thereof
|
|
KR20180091097A
(ko)
*
|
2015-12-23 |
2018-08-14 |
그리노파티온 바이오테크 게엠베하 |
보체 활성화를 억제하기 위한 폴리펩티드
|
|
CA3029106A1
(en)
|
2016-06-28 |
2018-01-04 |
Universitat Ulm |
Complement inhibitors and uses thereof
|
|
GB201800620D0
(en)
|
2018-01-15 |
2018-02-28 |
Univ Manchester |
C3b Binding Polypeptide
|
|
US20220195012A1
(en)
*
|
2019-04-13 |
2022-06-23 |
National Centre For Cell Science |
Daf-mcp chimeric proteins, process to manufacture the same and use of the chimeric protein for treating pathological conditions involving the complement system
|